The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Planned interim analysis of phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353.
Thomas J. George
Consultant or Advisory Role - Regeneron
Research Funding - Bayer; Bristol-Myers Squibb
Alison Marguerite Ivey
No relevant relationships to disclose
Karen Colleen Daily
No relevant relationships to disclose
Long H. Dang
No relevant relationships to disclose
Scott Watson
No relevant relationships to disclose
Renee Granicz
No relevant relationships to disclose
Margaret A. McEwan
No relevant relationships to disclose
Joanna Scian
No relevant relationships to disclose
Xiaomin Lu
No relevant relationships to disclose
Atif Iqbal
No relevant relationships to disclose
Sanda Tan
No relevant relationships to disclose
Ivan Zendejas
No relevant relationships to disclose
Carmen Joseph Allegra
No relevant relationships to disclose